A retrospective analysis of data identified predictors of cardiac adverse events in patients with CML undergoing treatment with tyrosine kinase inhibitors.
A review of data from patients with CML treated with TKIs identified risk factors for developing pulmonary hypertension in these patients.
Investigators report on outcomes for patients with chronic phase CML whose treatment was determined using an artificial intelligence-based model.
Age, marital status, and geographic location tended to influence use of oral anticancer therapy in older patients with metastatic RCC.
Researchers at UT MD Anderson Cancer Center in Houston present tools that support patient adherence to acalabrutinb in the setting of MCL.
A small study sought to determine if severe treatment-related skin rash could be treated without dose reduction or interruption in patients receiving imatinib for GIST.
[Cancer Management and Research] This review discusses advances in minimal residual disease monitoring in patients with CML, including its role in defining treatment response, choosing the best therapeutic strategy, and selecting patients who may be eligible for TKI discontinuation.
Fedratinib, a selective inhibitor of JAK2, was approved in 2019 by the US FDA for the treatment of certain groups of patients with myelofibrosis.
Results of LAST, the largest study on TKI discontinuation, support using patient-reported outcomes when monitoring remission and symptoms in patients who discontinue TKI therapy.
This study investigated patient adherence and persistence with trifluridine/tipiracil combination and regorafenib regimens for metastatic colorectal cancer, and also addressed whether sequence of administration had an effect on patient adherence and persistence to the therapies.
